Diagnostic Yield of Double-Dose Gadobutrol in the Detection of Brain Metastasis: Intraindividual Comparison with Double-Dose Gadopentetate Dimeglumine

References

1. 1.↵
   1. Chang SD,
   2. Lee E,
   3. Sakamoto GT,
   4. et al

   . Stereotactic radiosurgery in patients with multiple brain metastases. Neurosurg Focus 2000;9:e3

   PubMed
2. 2.↵
   1. Fuentes S,
   2. Delsanti C,
   3. Metellus P,
   4. et al

   . Brainstem metastases: management using gamma knife radiosurgery. Neurosurgery 2006;58:37–42, discussion 37–42

   CrossRefPubMed
3. 3.↵
   1. Yuh WT,
   2. Tali ET,
   3. Nguyen HD,
   4. et al

   . The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 1995;16:373–80

   Abstract/FREE Full Text
4. 4.↵
   1. Sze G,
   2. Johnson C,
   3. Kawamura Y,
   4. et al

   . Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. AJNR Am J Neuroradiol 1998;19:821–28

   Abstract
5. 5.↵
   1. Yuh WT,
   2. Engelken JD,
   3. Muhonen MG,
   4. et al

   . Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases. AJNR Am J Neuroradiol 1992;13:335–45

   Abstract/FREE Full Text
6. 6.↵
   1. Fellner F,
   2. Lungenschmid K,
   3. Fellner C,
   4. et al

   . Experiences with gadodiamide, a non-ionic contrast agent, in MRI of brain metastases. Rontgenpraxis 1998;51:203–11

   PubMed
7. 7.↵
   1. Akeson P,
   2. Larsson EM,
   3. Kristoffersen DT,
   4. et al

   . Brain metastases: comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging. Acta Radiol 1995;36:300–06

   PubMedWeb of Science
8. 8.↵
   1. Kuhn MJ,
   2. Picozzi P,
   3. Maldjian JA,
   4. et al

   . Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 2007;106:557–66

   CrossRefPubMed
9. 9.↵
   1. Rowley HA,
   2. Scialfa G,
   3. Gao PY,
   4. et al

   . Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol 2008;29:1684–91

   Abstract/FREE Full Text
10. 10.↵
    1. Tatsuno S,
    2. Hata Y,
    3. Tada S.

    . Double-dose Gd-DTPA: detectability of intraparenchymal brain metastasis [in Japanese]. Nippon Igaku Hoshasen Gakkai Zasshi 1996;56:855–59

    PubMed
11. 11.↵
    1. van der Molen AJ,
    2. Bellin MF

    . Extracellular gadolinium-based contrast media: differences in diagnostic efficacy. Eur J Radiol 2008;66:168–74

    CrossRefPubMed
12. 12.↵
    1. Vogl TJ,
    2. Friebe CE,
    3. Balzer T,
    4. et al

    . Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol: intraindividual evaluation of a phase II high dose study [in German]. Radiologe 1995;35:508–16

    PubMed
13. 13.↵
    1. Staks T,
    2. Schuhmann-Giampieri G,
    3. Frenzel T,
    4. et al

    . Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 1994;29:709–15

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Balzer JO,
    2. Loewe C,
    3. Davis K,
    4. et al

    . Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material. Eur Radiol 2003;13:2067–74

    CrossRefPubMed
15. 15.↵
    1. Vogler H,
    2. Platzek J,
    3. Schuhmann-Giampieri G,
    4. et al

    . Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol 1995;21:1–10

    CrossRefPubMed
16. 16.↵
    1. Tombach B,
    2. Heindel W

    . Value of 1.0- M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 2002;12:1550–56

    CrossRefPubMed
17. 17.↵
    1. Attenberger UI,
    2. Runge VM,
    3. Jackson CB,
    4. et al

    . Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T. Invest Radiol 2009;44:251–56

    CrossRefPubMed
18. 18.↵
    1. Giesel FL,
    2. Mehndiratta A,
    3. Risse F,
    4. et al

    . Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla. Acta Radiol 2009:50:521–30

    CrossRefPubMed
19. 19.↵
    1. Lemke AJ,
    2. Sander B,
    3. Balzer T,
    4. et al

    . Safety and use of gadobutrol in patients with brain tumors (phase III trial) [in German]. Rofo 1997;167:591–98

    PubMed
20. 20.↵
    1. Anzalone N,
    2. Gerevini S,
    3. Scotti R,
    4. et al

    . Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. Acta Radiol 2009:50:933–40

    CrossRefPubMed
21. 21.↵
    1. Thilmann O,
    2. Larsson EM,
    3. Bjorkman-Burtscher IM,
    4. et al

    . Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T. J Magn Reson Imaging 2005;22:597–604

    CrossRefPubMed
22. 22.↵
    1. Benner T,
    2. Reimer P,
    3. Erb G,
    4. et al

    . Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study. J Magn Reson Imaging 2000;12:371–80

    CrossRefPubMed
23. 23.↵
    1. Frenzel T,
    2. Lengsfeld P,
    3. Schirmer H,
    4. et al

    . Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43:817–28

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Le Duc G,
    2. Corde S,
    3. Charvet AM,
    4. et al

    . In vivo measurement of gadolinium concentration in a rat glioma model by monochromatic quantitative computed tomography: comparison between gadopentetate dimeglumine and gadobutrol. Invest Radiol 2004;39:385–93

    CrossRefPubMed
25. 25.↵
    1. Barker FG 2nd.

    . Surgical and radiosurgical management of brain metastases. Surg Clin North Am 2005;85:329–45

    CrossRefPubMed
26. 26.↵
    1. Essig M,
    2. Lodemann KP,
    3. Le-Huu M,
    4. et al

    . Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol 2006;41:256–63

    CrossRefPubMed
27. 27.↵
    1. Gasperini C,
    2. Paolillo A,
    3. Rovaris M,
    4. et al

    . A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. Magn Reson Imaging 2000;18:761–63

    CrossRefPubMed
28. 28.↵
    1. Goyen M,
    2. Herborn CU,
    3. Vogt FM,
    4. et al

    . Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: preliminary experience. J Magn Reson Imaging 2003;17:565–71

    CrossRefPubMed
29. 29.↵
    1. Ewing JR,
    2. Brown SL,
    3. Nagaraja TN,
    4. et al

    . MRI measurement of change in vascular parameters in the 9L rat cerebral tumor after dexamethasone administration. J Magn Reson Imaging 2008;27:1430–38

    CrossRefPubMed